Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics
暂无分享,去创建一个
Kohei Oishi | Donald E. Ingber | Rani K. Powers | Rachelle Prantil-Baun | Tristan Jordan | D. Ingber | S. Gilpin | R. Albrecht | M. Frieman | K. Benam | D. Hoagland | B. tenOever | Wen-Chun Liu | R. Prantil-Baun | Daniel Blanco-Melo | Benjamin E. Nilsson-Payant | S. Uhl | Rasmus Møller | K. Oishi | J. Logue | S. Weston | R. Haupt | Wen-Chun Liu | Tristan X. Jordan | Benjamin R. tenOever | Randy A. Albrecht | A. Jiang | Girija Goyal | Amanda Jiang | Matthew Frieman | M. McGrath | Kambez H. Benam | Longlong Si | Haiqing Bai | Melissa Rodas | Wuji Cao | Crystal Yuri Oh | Atiq Nurani | Danni Y. Zhu | Sarah E. Gilpin | K. Carlson | Daniel Blanco-Melo | Stuart Weston | James Logue | Rasmus Moller | Daisy Hoagland | Shu Horiuchi | Skyler Uhl | Robert Haupt | Marisa McGrath | Seong Min Kim | Kenneth Carlson | L. Si | Wuji Cao | H. Bai | Crystal Oh | Atiq Nurani | Shu Horiuchi | S. Kim | G. Goyal | M. Rodas | James Logue | Robert E. Haupt
[1] A. Azman,et al. Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease. , 2016, The New England journal of medicine.
[2] Krystal L. Matthews,et al. SARS-CoV-2 in vitro and SARS-CoV in vivo , 2020 .
[3] V. Sinou,et al. Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT®) following oral administration in African malaria patients , 2009, European Journal of Drug Metabolism and Pharmacokinetics.
[4] R. Schwartz,et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.
[5] K. Meng,et al. Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes , 2018, Science Advances.
[6] W. Dowling,et al. Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients , 2020, Nature Communications.
[7] H. Atkins,et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. , 2003, Cancer cell.
[8] Donald E. Ingber,et al. Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies? , 2020, Advanced science.
[9] V. Papayannopoulos. Neutrophil extracellular traps in immunity and disease , 2017, Nature Reviews Immunology.
[10] E. Holmes,et al. A new coronavirus associated with human respiratory disease in China , 2020, Nature.
[11] Lisa E. Hensley,et al. A screen of approved drugs and molecular probes identifies therapeutics with anti–Ebola virus activity , 2015, Science Translational Medicine.
[12] Krystal L. Matthews,et al. FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro , 2020, bioRxiv.
[13] Xilong Deng,et al. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial , 2020, Med.
[14] Thomas C. Ferrante,et al. Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro , 2015, Nature Methods.
[15] M. Dolovich,et al. Airway Epithelial Cell Cilia and Obstructive Lung Disease , 2016, Cells.
[16] Y. Guan,et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? , 2002, The Lancet.
[17] M. Rawlins,et al. Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers. , 1986, British journal of clinical pharmacology.
[18] David Shum,et al. Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs , 2020, Antimicrobial Agents and Chemotherapy.
[19] Kathryn L. Schornberg,et al. FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection , 2013, Science Translational Medicine.
[20] Emily G McDonald,et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.
[21] M. Estes,et al. Human organoid cultures: transformative new tools for human virus studies. , 2018, Current opinion in virology.
[22] S. Trottier,et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial , 2000, The Lancet.
[23] D. Ingber,et al. Biology-Inspired Microphysiological Systems to Advance Patient Benefit and Animal Welfare in Drug Development , 2020, ALTEX.
[24] André Machado Siqueira,et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.
[25] Joshua C. Johnson,et al. In Vivo Activity of Amodiaquine against Ebola Virus Infection , 2019, Scientific Reports.
[26] Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs , 2020, Antimicrobial Agents and Chemotherapy.
[27] S. Mubareka,et al. The lung microvascular endothelium as a therapeutic target in severe influenza. , 2013, Antiviral research.
[28] Tony Y. Hu,et al. Insights from nanomedicine into chloroquine efficacy against COVID-19 , 2020, Nature Nanotechnology.
[29] D. Ingber,et al. Reconstituting Organ-Level Lung Functions on a Chip , 2010, Science.
[30] Q. Bassat,et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.
[31] L. Naesens,et al. Airway proteases: an emerging drug target for influenza and other respiratory virus infections , 2017, Current Opinion in Virology.
[32] W. Simonson. Influenza treatment with antiviral medications. , 2019, Geriatric Nursing.
[33] Myrtle Davis,et al. Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: a biopharmaceutical perspective. , 2019, Lab on a chip.
[34] Avner Schlessinger,et al. ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI , 2012 .
[35] Kazuo Takayama. In Vitro and Animal Models for SARS-CoV-2 research , 2020, Trends in Pharmacological Sciences.
[36] M. Chan,et al. Use of ex vivo and in vitro cultures of the human respiratory tract to study the tropism and host responses of highly pathogenic avian influenza A (H5N1) and other influenza viruses. , 2013, Virus research.
[37] Agranulocytosis associated with the use of amodiaquine for malaria prophylaxis. , 1986, MMWR. Morbidity and mortality weekly report.
[38] D. Stuart,et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein , 2016, Nature.
[39] Daniel C Leslie,et al. A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice , 2012, Science Translational Medicine.
[40] Fumihiro Kato,et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells , 2020, Proceedings of the National Academy of Sciences.
[41] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[42] Carlos F. Ng,et al. On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology , 2020, Nature Biomedical Engineering.
[43] H. Clevers,et al. Tropism, replication competence, and innate immune responses of influenza virus: an analysis of human airway organoids and ex-vivo bronchus cultures. , 2018, The Lancet. Respiratory medicine.
[44] Masahiro Yoshida,et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes , 2020, Nature Medicine.
[45] P. Olliaro,et al. Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers , 2008, European Journal of Clinical Pharmacology.
[46] Yan Liu,et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.
[47] Richard Novak,et al. Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips , 2020, Nature Biomedical Engineering.
[48] K. Hattermann,et al. Susceptibility of different eukaryotic cell lines to SARS-coronavirus , 2005, Archives of Virology.
[49] K. To,et al. Differentiated human airway organoids to assess infectivity of emerging influenza virus , 2018, Proceedings of the National Academy of Sciences.
[50] Andrea Marzi,et al. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.
[51] Lisa E. Gralinski,et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract , 2020, Cell.
[52] Mahadevabharath R. Somayaji,et al. Physiologically Based Pharmacokinetic and Pharmacodynamic Analysis Enabled by Microfluidically Linked Organs-on-Chips. , 2018, Annual review of pharmacology and toxicology.